Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABSORB: PK/PD of Rivaroxaban in Bariatric Surgery and Morbid Obesity
NCT04180436Phase 1Completed
- Sponsor
- Centre Hospitalier Universitaire de Brest
- Start
- Jan 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rivaroxaban in thrombosis (4 arms), sponsored by Centre Hospitalier Universitaire de Brest. Primary endpoints: Area Under the Curve of rivaroxaban at 8 days, Maximum Concentration of rivaroxaban at 8 days and 1 more. Started Jan 2020; status: completed.
02
Drugs
rivaroxaban
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT04180436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04180436.